Learn about Cytokine Release Syndrome-CRS


Cytokine release is a systemic inflammatory response syndrome caused by complications of certain diseases or when the immune system overreacts to an infection. To treat CRS, doctors must resort to measures to reduce the immune response...

1. What is CYtokine-CRS?


Cytokines are small proteins that help the body's cells interact with each other. When the immune system detects a threat, the cells release cytokines to coordinate the body's response.
Cytokine-releasing syndrome-CRS is a systemic inflammatory response syndrome caused by complications of certain diseases or when the immune system is stimulated to overreact to an infection, possibly as a side effect. of certain types of immunotherapy , especially those involving T lymphocytes .
Cytokines are released in large amounts into the body, these are known as cell messengers to help direct the immune response. However, when cytokine levels are too high, inflammatory activity can be increased. This can cause harmful levels of inflammation and interfere with some of the body's normal functions. In severe cases, CRS can cause organ failure and even death.

2. Causes of Cytokine Release Syndrome-CRS


The main cause of Cytokine-releasing syndrome-CRS is that after immunotherapy treatment, the body activates T lymphocytes to fight cancer. These therapies triggered an excessive immune inflammatory response due to the release of cytokines.
Typically in childhood cancer, the most commonly used immunotherapies associated with CRS are tisagnlecleucel and blinatumomab.
Tisagenlecleucel (Kymriah®): As a CAR T-cell immunotherapy. Its mechanism of action is to use a technique to give T cells special receptors. This is called a chimeric antigen receptor (CAR). These receptors help T cells recognize and attack cancer cells. Blinatumomab (Blincyto®): Is a monoclonal antibody. It stimulates bispecific T-cell engager BiTE. The drug's mechanism of action is to work by making T cells target CD19 (a protein found on certain types of leukemia cells). CAR immunotherapy in pediatric cancer is currently most commonly used in children with relapsed or refractory acute lymphoblastic leukemia (ALL).
Cytokines
Cytokine là những protein nhỏ, giúp cho các tế bào của cơ thể có sự tương tác với nhau

3. Cytokine-CRS . Release Symptoms


Cytokine release syndrome (CRS) can cause a number of symptoms such as fever, headache, and nausea. These symptoms can quickly progress to serious.
Symptoms of CRS are caused by excessive immune responses in the body. It can affect multiple organs, and in some cases, CRS can cause serious changes that threaten heart, lung, kidney, liver and brain function and even be life-threatening.
3.1 Heart and Vascular Symptoms When CRS affects the cardiovascular system, accompanying symptoms may include:
Increased heart rate; Irregular heartbeat; Reduced heart function; Blood pressure drops; Edema phenomenon. 3.2 Brain and Nervous System Symptoms When CRS affects the brain and nervous system, central nervous system related symptoms may include:
Confusion; Dizziness ; Movements that coordinate activity and movement; Seizures; Illusion; Difficulty swallowing; 3.3 Lung symptoms When CRS affects the lungs, some symptoms may appear such as:
Persistent cough; Decreased respiratory function of the lungs; Shortness of breath or difficulty breathing. In addition, CRS can also cause problems affecting kidney and liver function.
liệu pháp miễn dịch
Sau khi điều trị liệu pháp miễn dịch, những bệnh nhân có nguy cơ sẽ được theo dõi trong khoảng 1 tháng

4. Treatment of Cytokine Release Syndrome-CRS


People who are treated with immunotherapies or infections are at a higher risk of developing CRS. CRS usually develops within 3 to 14 days of treatment with T-lymphocyte-based immunotherapy. It will usually begin with fever and flu-like symptoms. However, it can worsen quickly and cause serious illness. Therefore, early treatment is very important.
Treatment of Cytokine-releasing syndrome-CRS includes monitoring and supportive care to manage symptoms. Depending on the severity of the disease, some patients may need special care and medications to reduce the immune response (immunosuppressants).
After immunotherapy, at-risk patients will be monitored for about 1 month. Symptoms will usually improve within 1 to 2 weeks. Most patients will have no long-term problems from the cytokine release syndrome.
Go to the nearest medical facility if you develop symptoms of CRS such as fever, cough, headache and diarrhea that suddenly become more severe or the condition persists for several days. More serious symptoms such as difficulty breathing, confusion or changes in organ function or heart rhythm problems require immediate medical attention. Currently, Vinmec International General Hospital is one of the leading prestigious hospitals in the country, trusted by a large number of patients for medical examination and treatment. Not only the physical system, modern equipment: 6 ultrasound rooms, 4 DR X-ray rooms (1 full-axis machine, 1 light machine, 1 general machine and 1 mammography machine) , 2 DR portable X-ray machines, 2 multi-row CT scanner rooms (1 128 rows and 1 16 arrays), 2 Magnetic resonance imaging rooms (1 3 Tesla and 1 1.5 Tesla), 1 room for 2 levels of interventional angiography and 1 room to measure bone mineral density.... Vinmec is also the place to gather a team of experienced doctors and nurses who will greatly assist in diagnosis and detection. early signs of abnormality in the patient's body. In particular, with a space designed according to 5-star hotel standards, Vinmec ensures to bring the patient the most comfort, friendliness and peace of mind.

Để đặt lịch khám tại viện, Quý khách vui lòng bấm số HOTLINE hoặc đặt lịch trực tiếp TẠI ĐÂY. Tải và đặt lịch khám tự động trên ứng dụng MyVinmec để quản lý, theo dõi lịch và đặt hẹn mọi lúc mọi nơi ngay trên ứng dụng.

Bài viết này được viết cho người đọc tại Sài Gòn, Hà Nội, Hồ Chí Minh, Phú Quốc, Nha Trang, Hạ Long, Hải Phòng, Đà Nẵng.

136 lượt đọc

Dịch vụ từ Vinmec

Bài viết liên quan
  • Nivolumab
    Nivolumab có tác dụng gì? Cách sử dụng như thế nào?

    Nivolumab là một trong những thuốc mới hiện đang được sử dụng trong điều trị ung thư tại các bệnh viện thuộc Hệ thống y tế Vinmec. Bài viết dưới đây sẽ cung cấp thêm một số thông tin chung ...

    Đọc thêm
  • Pralatrexate
    Công dụng thuốc Pralatrexate (Folotyn)

    Thuốc Pralatrexate hay còn gọi là thuốc Folotyn- là một loại thuốc trị ung thư. Thuốc Pralatrexate được sử dụng để điều trị ung thư hạch tế bào T đã lan rộng khắp cơ thể. Đồng thời, đây cũng là ...

    Đọc thêm
  • yescarta
    Công dụng thuốc Yescarta

    Yescarta (Axicabtagene ciloleucel) là một dịch thể đục được đưa vào cơ thể qua đường truyền tĩnh mạch. Dung dịch này chứa tế bào T tự thân đã được biến đổi cấu trúc gen nhắm vào CD19.

    Đọc thêm
  • tecartus
    Công dụng thuốc Tecartus

    Thuốc Tecartus là một dược phẩm sử dụng trong điều trị bệnh ung thư thông qua liệu pháp nâng miễn dịch. Khả năng tự động miễn dịch của tế bào T được kích hoạt giúp cho tế bào ung thư ...

    Đọc thêm
  • Idecabtagene vicleucel
    Công dụng thuốc Idecabtagene Vicleucel

    Thuốc Idecabtagene vicleucel thuộc nhóm liệu pháp miễn dịch Car-T. Vậy dùng thuốc Idecabtagene để làm gì, loại thuốc này có tác dụng gì và cách sử dụng như thế nào?

    Đọc thêm